Pharma | 30 July 2022 | Opinion
Is Industry 4.0 Promising The Moon?
As pharma shifts from generic drugs to personalised medicines, it has become apparent that conventional system...Read more
Healthcare | 30 July 2022 | Opinion
Drones also referred to as unmanned aerial vehicles (UAV), are slowly making their presence felt in the health...Read more
Specials | 30 June 2022 | Opinion
From Hazy to Crystal Clear Picture of Compensation Trends
Compensation is always tricky to determine, both as a professional and for organisations. Across all markets, ...Read more
Digital Health | 30 July 2022 | Opinion
“APAC has potential to be a strong leader in personalised healthcare with Singapore ranking at top”
How is GE Healthcare helping to enhance the concept of precision healthcare within APAC? Precision heal...Read more
Medical Devices | 28 June 2022 | Opinion
"Asia Pacific is one of the focused areas for Freudenberg Medical"
What will be your latest innovations in the healthcare and pharma industry? Freudenberg is a global t...Read more
Contract Manufacturing | 30 July 2022 | Opinion
How CDMOs are Adapting to New mRNA Tech Demands
The COVID-19 pandemic highlighted the successful development and utilisation of mRNA vaccines. This has encour...Read more
North America | 24 June 2022 | News
Merck unveils €59 M CDMO facility for critical cancer therapies
Merck has announced that its Life Science business sector has doubled its high-potent active pharmaceutical in...Read more
Keeping Pace with MUTATING VIRUSES
A surge in the pandemic has forced the pharma industry to deliver a wide-spectrum vaccine to fight mutation-prone SARS-CoV-2, pledging to prevent future outbreaks. WHO states that the most extensive vaccination campaign in history is providing prophylactic results by delivering more than 12 billion doses of the COVID-19 vaccine, protecting 60 per cent of the global population as of June 2022. Now the next-generation COVID-19 vaccines are countering the challenge of enhancing the immune response to tackle the emerging COVID-19 variants. It is therefore imperative to remain vigilant and upgrade vaccine candidates to emerging virus sublineages. In order to gain a competitive position in the market, vaccine manufacturers are investing in advanced platform technologies. Let’s take a closer look at some of these leading vaccines approved in APAC as broad spectrum virucide inhibitors.
For Feedback Email Us: communications@biospectrumasia.com
1 North Bridge Road,
#08-08 High Street Centre,
Singapore 179094
Email : communications@biospectrumasia.com
